JSSH(SZ:000518)2021-04-16 16:00Financial Performance - The company's operating revenue for 2020 was CNY 505,399,427.19, representing a 20.94% increase compared to CNY 417,878,239.86 in 2019[18]. - The net profit attributable to shareholders for 2020 was CNY 27,295,103.63, a significant increase of 90.46% from CNY 14,330,773.52 in 2019[18]. - The net cash flow from operating activities reached CNY 100,233,420.61, up 70.95% from CNY 58,632,435.61 in the previous year[18]. - The basic earnings per share for 2020 was CNY 0.0265, reflecting a 90.65% increase from CNY 0.0139 in 2019[18]. - Total revenue for 2020 reached ¥505.40 million, a year-on-year increase of 20.94% compared to ¥417.88 million in 2019[39]. - The company reported a total comprehensive income of CNY 27.66 million for 2020, compared to CNY 17.50 million in 2019, marking a growth of 58.2%[189]. - The company’s total operating costs rose to CNY 474.97 million in 2020 from CNY 387.01 million in 2019, an increase of 22.6%[191]. Assets and Liabilities - Total assets at the end of 2020 were CNY 823,707,532.72, a decrease of 10.06% from CNY 915,826,035.12 at the end of 2019[18]. - The total liabilities also decreased from CNY 255.51 million in 2019 to CNY 138.66 million in 2020, a reduction of 45.68%[180]. - The total current assets amounted to CNY 668,928,560.78 as of December 31, 2020, down from CNY 755,852,139.94 in the previous year, indicating a decrease of about 11.5%[178]. - The total inventory accounted for 55.35% of the total assets as of December 31, 2020, highlighting the significant role of inventory in the company's asset structure[171]. Revenue Segmentation - The core products of the subsidiary Beijing Four环生物制药 experienced a slight decline in revenue, totaling CNY 308,814,960.93, down 8.51% year-on-year due to the impact of the pandemic and medical reform policies[35]. - The timber business of the wholly-owned subsidiary Guangxi Intercontinental Forestry Investment achieved operating revenue of CNY 143,858,377.52, a significant increase of 374.20% year-on-year[35]. - Domestic sales accounted for 98.95% of total revenue at ¥500.07 million, up from 97.64% in 2019[40]. - Pharmaceutical segment revenue decreased by 19.68% to ¥308.81 million, accounting for 61.10% of total revenue[39]. - The timber segment saw a significant increase in revenue by 21.20% to ¥143.86 million, representing 28.46% of total revenue[39]. Research and Development - The company has five invention patents and three new drug certificates, indicating a strong focus on research and development in the biopharmaceutical sector[32]. - The company reported a significant increase in the number of R&D personnel, rising by 166.67% from 6 to 16[54]. - Research and development expenses amounted to ¥40,704,876.05, representing 8.05% of total revenue, a decrease from 10.29% in 2019[54]. Governance and Compliance - The company is actively enhancing its internal control system and compliance management following administrative penalties from the China Securities Regulatory Commission[36]. - The company emphasizes the protection of minority shareholders' rights and has established a comprehensive corporate governance structure[106]. - The company faced penalties for information disclosure violations, including warnings and fines for several directors and senior management[88]. - The audit opinion was a standard unqualified opinion, confirming the fair presentation of the financial statements[165]. Shareholder Information - The total number of ordinary shareholders increased from 132,319 to 142,671, indicating a growth of approximately 7.5%[117]. - The largest shareholder, Wang Hongming, holds 14.00% of the shares, amounting to 144,138,394 shares, which are currently pledged[117]. - The company has no controlling shareholders, with the top five shareholders holding similar stakes, promoting a balanced ownership structure[120]. Operational Strategies - The company plans to continue focusing on its core products, including Delu Sheng and Xin Li Sheng, while actively expanding into new markets to increase market share[68]. - The company aims to enhance its production and sales management to reduce pharmaceutical sales expenses and improve operational efficiency[72]. - The company plans to expand its landscaping business to create new profit growth points and improve overall competitiveness[69]. Cash Flow and Financial Management - The total amount of cash inflow from operating activities was ¥470,125,282.10, up 13.22% from ¥415,232,539.07 in 2019[55]. - Cash inflow from financing activities totaled ¥17,200,000.00 in 2020, down from ¥106,000,000.00 in 2019, a decrease of about 83.8%[197]. - The company reported a cash outflow of ¥3,219,138.31 related to other operating activities in 2020, down from ¥4,554,828.80 in 2019, showing a decrease of approximately 29.2%[198]. Employee and Management Structure - The total number of employees in the company is 288, with 238 in major subsidiaries and 7 in the parent company[139]. - The company has a professional composition of 128 production personnel, 22 sales personnel, 79 technical personnel, 12 financial personnel, and 47 administrative personnel[139]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounts to 2.23 million yuan[139]. Audit and Internal Controls - The internal control audit report indicated that the company maintained effective financial reporting internal controls as of December 31, 2020[160]. - There were no significant internal control deficiencies reported during the period[157]. - The company has established an independent financial department and accounting system, ensuring financial decisions are made independently[149].